Table of Contents
Advertisement
Parameter
Hematocrit (%)
Hemoglobin (g/dL)
Platelet (x 10
/L)
9
WBC (x 10
/L)
9
Granulocyte (x
10
/L)
9
Lymph/Mono
(x10
/L)
9
The hematocrit results shown above refl ect the calibration methods of the Coulter or Sysmex analyzers used in the correlation
study. The QBC STAR software has been calibrated to match the international reference standard for microhematocrit (MHCT)
technology. The data shown in the table below were obtained by comparing the QBC STAR results against the microhematocrit
reference method.
12
Parameter
Microhematocrit
(%)
* Products of Coulter Electronics, Hialeah, FL and TOA Medical Electronics, Kyoto, Japan.
Interfering Substances
•
Hemolysis: Do not perform tests on visibly hemolyzed blood specimens.
•
Bilirubin: No effects on test results have been observed at bilirubin concentrations up to 20 mg/dL.
•
Triglycerides: No effects on test results have been observed at triglyceride concentrations up to 1,800 mg/dL.
•
Coumadin: Anticoagulant therapy has been shown to have no clinically signifi cant effect on performance.
•
Doxorubicin: Treatment with the anthracyclic drug Doxorubicin does not appear to interfere with the QBC test
method.
8
•
Other Drugs: The effects of other potentially interfering drugs and their metabolites on QBC tests have not been
established.
9, 10
L–000867(A)
Cor-
relation
Slope
Coeffi -
cient
0.983
0.973
0.984
0.982
0.962
0.935
0.974
1.124
0.972
0.991
0.987
1.206
Correlation
Slope
Intercept
Coeffi cient
0.986
1.023
–0.650
5 – Performance and Limitations
Cell
Inter-
QBC
Counter
cept
Mean
Mean
2.572
36.5
34.8
0.387
12.1
12.0
17.701
244
242
–0.936
10.4
10.1
0.152
7.0
7.0
–0.419
3.3
3.1
Cell
QBC
Counter
Mean
Mean
36.5
36.3
Number
Range of
of Sam-
Values
ples
15.7
646
– 61.7
5.2
638
– 18.5
23 – 913
558
1.6
535
– 92.9
0.8
535
– 45.0
0.8
535
– 89.9
Range of
Number of
Values
Samples
15.7
646
– 61.9
8
8
8
5–3
Hide quick links:
Advertisement
Table of Contents
